ACRV

Acrivon Therapeutics, Inc. (ACRV) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology medicines using its proprietary AP3 platform. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. As of May 8, 2026, there were 42,801,729 shares of common stock outstanding.

Key Financial Metrics

Note: The company has no debt obligations listed on the balance sheet. Total liabilities consist primarily of accrued expenses and operating lease liabilities ($12.3 million).

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased by $1.8 million (8.1%) to $19.9 million. This was driven by a $1.5 million decrease in General and Administrative (G&A) expenses, largely due to reduced stock-based compensation. Research and Development (R&D) expenses decreased slightly by $0.2 million.
• Interest Income: Interest income declined by $1.0 million to $0.99 million, reflecting lower yields or balances on investments compared to the prior year.
• Equity Transactions: During Q1 2026, all pre-funded warrants from the April 2024 Private Placement were exercised via cashless exercise, resulting in the issuance of approximately 7.06 million shares. No pre-funded warrants remain outstanding.
• Investments: Short-term investments decreased from $77.1 million to $63.7 million as the company utilized proceeds from maturities ($30.0 million) to fund operations, while purchasing new investments ($16.9 million).

Guidance, Outlook, and Management Commentary

• Liquidity Outlook: Management states that existing cash, cash equivalents, and investments of $97.7 million (as of March 31, 2026), combined with $7.3 million in net proceeds from an "at-the-market" (ATM) offering in April 2026, are sufficient to fund operations into the third quarter of 2027.
• Clinical Progress:
  • ACR-368 (Prexasertib): Interim data from the Phase 2b trial in endometrial cancer (EC) showed a confirmed overall response rate (ORR) of 52% in serous EC subjects. New arms (3 and 4) have been initiated to test the drug in "all-comer" serous EC patients, with and without ultra-low dose gemcitabine sensitization.
  • ACR-2316: The Phase 1/2 trial is advancing with weekly dosing established. Initial data showed favorable tolerability and clinical activity (tumor shrinkage) in small cell lung cancer (SCLC) and squamous non-small cell lung cancer (NSCLC).
• Strategic Shift: The company terminated its companion diagnostic agreement with Akoya Biosciences in February 2026. Acrivon has established an internal CLIA-certified laboratory to perform the OncoSignature test in-house, gaining full control over the diagnostic development and commercialization.
• Risks: The company expects to continue incurring significant losses. Future funding requirements depend on clinical trial progress, regulatory approvals, and the ability to raise additional capital. Failure to secure funding could force delays in development.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the projection to fund operations into Q3 2027, considering the burn rate of ~$20 million per quarter.
• ATM Proceeds: Confirm the closing details and net proceeds of the April 2026 ATM offering ($7.3 million) and its impact on share count dilution.
• Clinical Data: Review the full interim data presentation from the ESGO Annual Congress regarding the 52% ORR in serous endometrial cancer for ACR-368.
• Diagnostic Capability: Assess the operational readiness and regulatory status of the new internal CLIA laboratory replacing the Akoya partnership.
• Stock-Based Compensation: Monitor the trend in stock-based compensation, which dropped significantly in Q1 2026 ($2.2 million vs $3.8 million in Q1 2025), and its potential impact on future expense guidance.